Laura Divine, MD
Gynecologic Oncology · Dallas, TXNPI 1255659173
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 75.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,003 and has fallen 93.7% since, to $127 in 2025.
Across 36 payments — averaging $105.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$506
- Myriad Genetic Laboratories, Inc.$149
- Clovis Oncology, Inc.$102
- Merck$78
- Innovation Technologies Inc$37
- plus $62 from 3 others
Across 10 payments — averaging $7164.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$62K
- GSK$10K
What the payments were for
- Speaking & faculty fees$50013%
- Travel & lodging$1,65744%
- Food & beverage$1,51740%
- Education$1023%
- Gifts$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $2,858 |
| AstraZeneca | 9 | $506 |
| Myriad Genetic Laboratories, Inc. | 2 | $149 |
| Clovis Oncology, Inc. | 2 | $102 |
| Merck | 4 | $78 |
| Innovation Technologies Inc | 1 | $37 |
| Daiichi Sankyo Inc. | 1 | $29 |
| GSK | 1 | $17 |
| On Target Laboratories, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,916
- DA VINCI SP$500
- LYNPARZA$247
- PreciseTumor$109
How this compares
$3,793 in reported general payments places this provider in the 55th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 14 | $316,385 |
| EliquisApixaban | 16 | $17,716 |
| Megestrol Acetate | 15 | $1,066 |
| Gabapentin | 40 | $519 |
| Letrozole | 25 | $517 |
| Olanzapine | 28 | $201 |
| Levothyroxine Sodium | 15 | $177 |
| Prochlorperazine Maleate | 23 | $147 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $146 |
| Tramadol Hcl | 34 | $111 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Dallas
- Dustin MandersDallas$171K
- David MillerDallas$101K
- Thomas HeffernanDallas$95K
- Jayanthi LeaDallas$12K
- Jonathan OhDallas$7K
- Jessica GillenDallas$6K
- Brandon RoaneDallas$4K
- Bruce FineDallas$4K
- Erik KoonDallas$4K
- Alan MunozDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.